Sugi Predict

Sugi Predict / Compounds / SCHEMBL23364342

SCHEMBL23364342

SCHEMBL23364342

COc1cc2c(cc1OC)C(C1CCOCC1)N(c1ccnc(-c3ncccn3)n1)C2=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.38
▸ CYP3A4 P08684 3/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ CYP1A2 P05177 3/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ USP2 O75604 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ IDH1 O75874 5/20 0.34
▸ MAPT P10636 2/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ FGFR2 P21802 1/20 0.33
▸ FGFR3 P22607 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ADRA1B P35368 1/20 0.33
▸ HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23364445 1.00 KDM4E (0.38) KDM4ECYP3A4MAPK1CYP1A2CYP2C9
SCHEMBL23364247 1.00 KDM4E (0.38) KDM4ECYP3A4MAPK1CYP1A2CYP2C9
SCHEMBL24910706 0.93 KDM4E (0.40) KDM4ECYP3A4MAPK1CYP1A2CYP2C9
SCHEMBL23364264 0.91 KDM4E (0.41) KDM4ECYP3A4CYP1A2CYP2C9HSD17B10
SCHEMBL24910673 0.91 KDM4E (0.41) KDM4ECYP3A4CYP1A2CYP2C9HSD17B10
SCHEMBL23364299 0.91 KDM4E (0.41) KDM4ECYP3A4CYP1A2CYP2C9HSD17B10
SCHEMBL24911755 0.85 HCRTR1 (0.38) KDM4ECYP3A4CYP1A2ALDH1A1USP2
SCHEMBL23364316 0.78 CYP11B1 (0.38) KDM4ECYP3A4MAPK1CYP1A2CYP2C9
SCHEMBL23364303 0.78 CYP11B1 (0.38) KDM4ECYP3A4MAPK1CYP1A2CYP2C9
SCHEMBL23364277 0.78 KDM4E (0.37) KDM4ECYP3A4MAPK1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-01-19 — — US claimed
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-01-19 — — US disclosed
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-01-19 — — US disclosed
WO-2021097075-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, CDV3, HCCS KDM4E 1888/4885CYP3A4 182/4885MAPK1 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.